Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bmjspcare-2020-002589 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacogenomics-guided opioid management.
BMJ Support Palliat Care
December 2020
Department of Cancer Pharmacology & Pharmacogenomics, Levine Cancer Institute, Charlotte, North Carolina, USA.
Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach.
Addict Behav Rep
December 2017
Consultative Genomics, PLLC, 5909 West Loop South, Suite 310, Bellaire, TX 77401, United States.
Introduction: Opioid use disorder (OUD) is characterized by a problematic pattern of opioid use leading to clinically-significant impairment or distress. Opioid agonist treatment is an integral component of OUD management, and buprenorphine is often utilized in OUD management due to strong clinical evidence for efficacy. However, interindividual genetic differences in buprenorphine metabolism may result in variable treatment response, leaving some patients undertreated and at increased risk for relapse.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!